Phase 3 Clinical Trials With Primary Completion Dates in June 2016

This is a list of Phase 3 trials with primary completion dates in June 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ACORAcorda Therapeutics, Inc.2016-06-01Phase 3NCT02240030Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
AMPEAmpio Pharmaceuticals, Inc.2016-06-01Phase 3NCT02556710AP-003-B Study to Evaluate the Efficacy And Safety Of An Intra-Articular Injection Of Ampion™ In Adults With Pain With Osteoarthritis Of The Knee
ARRYArray BioPharma Inc.2016-06-01Phase 3NCT01909453Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
ARRYArray BioPharma Inc.2016-06-01Phase 3NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
CYADCelyad SA2016-06-01Phase 3NCT02317458Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) Trial THE CHART-2 TRIAL
DRRXDurect Corporation2016-06-01Phase 3NCT02450890Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
DSCIDerma Sciences, Inc.2016-06-01Phase 3NCT01840085Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use
EBIOEleven Biotherapeutics, Inc.2016-06-01Phase 3NCT02405039Study of EBI-005 in Dry Eye Disease (DED)
FGENFibroGen, Inc2016-06-01Phase 3NCT01887600Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
INSYInsys Therapeutics, Inc.2016-06-01Phase 3NCT02634788Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain
LJPCLa Jolla Pharmaceutical Company2016-06-01Phase 3NCT02338843A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
MSTXMast Therapeutics, Inc.2016-06-01Phase 3NCT02449616Evaluation of Repeat Administration of Purified Poloxamer 188
MYGNMyriad Genetics, Inc.2016-06-01Phase 3NCT01847274A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
NLNKNewLink Genetics Corporation2016-06-01Phase 3NCT01072981Immunotherapy Study for Surgically Resected Pancreatic Cancer
ONTXOnconova Therapeutics, Inc.2016-06-01Phase 3NCT01928537Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
PRAHPRA Health Sciences, Inc.2016-06-01Phase 3NCT02333071A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
PTNPalatin Technologies, Inc.2016-06-01Phase 3NCT02333071A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
RDYDr. Reddy's Laboratories Ltd2016-06-01Phase 3NCT02569853DFN-11 Injection in Episodic Migraine With or Without Aura
RIGLRigel Pharmaceuticals, Inc.2016-06-01Phase 3NCT02076412A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
RIGLRigel Pharmaceuticals, Inc.2016-06-01Phase 3NCT02076399A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
RTRXRetrophin, Inc.2016-06-01Phase 3NCT01438411Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis
RVNCRevance Therapeutics, Inc.2016-06-01Phase 3NCT02580370Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines
SGYPSynergy Pharmaceuticals, Inc.2016-06-01Phase 3NCT02387359The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
SGYPUSynergy Pharmaceuticals, Inc.2016-06-01Phase 3NCT02387359The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
TBPHTheravance Biopharma, Inc.2016-06-01Phase 3NCT02512510Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
TBPHTheravance Biopharma, Inc.2016-06-01Phase 3NCT02459080Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
TSROTESARO, Inc.2016-06-01Phase 3NCT01847274A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer